Illumina Inc. and Qiagen N.V. have been on a collision course since 2012. The two are in a race to move next-generation gene sequencing technology beyond big research laboratories and into everyday clinical settings.
Patent litigation in two federal district courts, the Patent Trial and Appeal Board and the U.S. Court of Appeals for the Federal Circuit came to a head Sept. 9 when U.S. District Judge William Alsup of the Northern District of California ordered Netherlands-based Qiagen to stop making and selling its GeneReader product in the United States.
